Departments of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fujian, China.
J Cell Mol Med. 2022 Jan;26(2):410-421. doi: 10.1111/jcmm.17093. Epub 2021 Dec 10.
Metastasis contributes to treatment failure in nasopharyngeal carcinoma (NPC) patients. Our study aimed at elucidating the role of insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) in NPC metastasis and the underlying mechanism involved. IGF2BP3 expression in NPC was determined by bioinformatics, quantitative polymerase chain reaction and immunohistochemistry analyses. The biological function of IGF2BP3 was investigated by using in vitro and in vivo studies. In this study, IGF2BP3 mRNA and protein levels were elevated in NPC tissues. In addition, IGF2BP3 exerted an oncogenic role by promoting epithelial-mesenchymal transition (EMT), thereby inducing NPC cell migration and invasion. Further studies revealed that IGF2BP3 regulated the expression of key regulators of EMT by activating AKT/mTOR signalling, thus stimulating NPC cell migration and invasion. Remarkably, targeting IGF2BP3 delayed NPC metastasis through attenuating p-AKT and vimentin expression and inducing E-cadherin expression in vivo. Moreover, IGF2BP3 protein levels positively correlated with distant metastasis after initial treatment. Importantly, IGF2BP3 expression served as an independent prognostic factor in predicting the overall survival and distant metastasis-free survival of NPC patients. This work identifies IGF2BP3 as a novel prognostic marker and a new target for NPC treatment.
转移导致鼻咽癌 (NPC) 患者的治疗失败。我们的研究旨在阐明胰岛素样生长因子 2 mRNA 结合蛋白 3 (IGF2BP3) 在 NPC 转移中的作用及其涉及的潜在机制。通过生物信息学、定量聚合酶链反应和免疫组织化学分析确定 NPC 中的 IGF2BP3 表达。通过体外和体内研究研究了 IGF2BP3 的生物学功能。在这项研究中,NPC 组织中 IGF2BP3 mRNA 和蛋白水平升高。此外,IGF2BP3 通过促进上皮-间充质转化 (EMT) 发挥致癌作用,从而诱导 NPC 细胞迁移和侵袭。进一步的研究表明,IGF2BP3 通过激活 AKT/mTOR 信号通路调节 EMT 的关键调节剂的表达,从而刺激 NPC 细胞迁移和侵袭。值得注意的是,通过在体内减弱 p-AKT 和波形蛋白的表达并诱导 E-钙粘蛋白的表达,靶向 IGF2BP3 可延迟 NPC 的转移。此外,IGF2BP3 蛋白水平与初始治疗后的远处转移呈正相关。重要的是,IGF2BP3 表达可作为 NPC 患者总生存和无远处转移生存的独立预后因素。这项工作确定 IGF2BP3 是 NPC 治疗的新的预后标志物和新靶点。